Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 43, Pages 12250-12255Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1600067113
Keywords
cholangiocarcinoma; Notch; noncanonical; bile duct; cancer
Categories
Funding
- Cancer Research UK [12946, 11650, 14889] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [20409, 21139] Funding Source: researchfish
- Cancer Research UK [12946, 11650, A11650] Funding Source: Medline
- Medical Research Council [MR/K017047/1] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
The prognosis of cholangiocarcinoma (CC) is dismal. Notch has been identified as a potential driver; forced exogenous overexpression of Notch1 in hepatocytes results in the formation of biliary tumors. In human disease, however, it is unknown which components of the endogenously signaling pathway are required for tumorigenesis, how these orchestrate cancer, and how they can be targeted for therapy. Here we characterize Notch in human-resected CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted to biliary epithelia and CC induced using the hepatocarcinogen thioacetamide. We find that across species, the atypical receptor NOTCH3 is differentially overexpressed; it is progressively up-regulated with disease development and promotes tumor cell survival via activation of PI3k-Akt. We use genetic KO studies to show that tumor growth significantly attenuates after Notch3 deletion and demonstrate signaling occurs via a noncanonical pathway independent of the mediator of classical Notch, Recombinant Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJ). These data present an opportunity in this aggressive cancer to selectively target Notch, bypassing toxicities known to be RBPJ dependent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available